Active, not recruitingPhase 3NCT04576156
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Geron Corporation
- Principal Investigator
- Faye FellerGeron Corporation
- Intervention
- Imetelstat(drug)
- Enrollment
- 327 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- University of California-San Diego/Moores UCSD Cancer Center, La Jolla, California, United States
- UCLA David Geffen School of Medicine, Los Angeles, California, United States
- Smilow Cancer Center at YNHH, New Haven, Connecticut, United States
- BRCR Medical Center Inc, Plantation, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Maryland Oncology Hematology, Rockville, Maryland, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Gabrail Cancer Center, Canton, Ohio, United States
- Prairie Lakes Health Care System, Inc., Watertown, South Dakota, United States
- Oncology Consultants, Houston, Texas, United States
- The University of Texas MD, Houston, Texas, United States
- Community Cancer Trials of Utah, Ogden, Utah, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04576156 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong